Dynamic Antigen Expression and Intrinsic CTL Resistance in HIV Reservoir Clones

Area of Science:

• Immunology
• Virology
• HIV Research

Background:

• Lifelong persistence of HIV reservoirs (clonally expanded CD4+ T-cells with rebound-competent proviruses) during antiretroviral therapy (ART) is a major hurdle for viral eradication.
• The latent nature of these reservoirs has resisted pharmacological reversal, necessitating exploration of immune-based strategies.
• Previous research suggests intrinsic pro-survival mechanisms contribute to the persistence of these rare reservoir-harboring cells.

Purpose of the Study:

• To isolate and characterize authentic reservoir clones (ARCs) that persist despite producing infectious HIV.
• To investigate the vulnerabilities and resistance mechanisms of ARCs to sustained immune pressure, particularly from cytotoxic T-lymphocytes (CTLs).
• To identify potential therapeutic targets for immune-based HIV cure strategies.

Main Methods:

• Isolation and characterization of authentic reservoir clones (ARCs) from HIV-infected individuals on ART.
• Assessment of viral protein expression in ARCs under various stimulation conditions (TCR, mitogenic).
• Co-culture of ARCs with cytotoxic T-lymphocytes (CTLs) to evaluate immune pressure and antigenic vulnerability.
• Analysis of intrinsic resistance mechanisms, including oxidative stress and response to desferoxamine.

Main Results:

• ARCs were identified as robustly proliferating cells producing infectious virus, with only a small fraction expressing HIV proteins at any given time.
• Sustained CTL pressure significantly reduced ARC clonal expansion (>90%), revealing time-integrated antigenic vulnerability.
• A regulatory T-cell ARC demonstrated intrinsic resistance to CTLs, linked to low oxidative stress, which was reversed by desferoxamine.

Conclusions:

• Sustained CTL pressure can effectively target and reduce HIV reservoir clones, highlighting immune pressure as a viable strategy.
• Intrinsic resistance mechanisms, such as those observed in regulatory T-cell ARCs, represent critical targets for therapeutic intervention.
• Targeting these resistance pathways, potentially using agents like desferoxamine, could advance immune-based HIV cure strategies.